Quillivant Xr

— THERAPEUTIC CATEGORIES —
  • ADHD

Quillivant Xr Generic Name & Formulations

General Description

Methylphenidate HCl ext-rel 5mg/mL; pwd for oral susp after reconstitution.

Pharmacological Class

CNS stimulant.

How Supplied

Bottles (w. oral dosing dispenser)—60mL, 120mL, 150mL, 180mL

Manufacturer

Generic Availability

NO

Mechanism of Action

The mode of therapeutic action in ADHD is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Quillivant Xr Indications

Indications

Attention deficit hyperactivity disorder.

Quillivant Xr Dosage and Administration

Adults and Children

<6yrs: not established. ≥6yrs: Individualize. Shake bottle for 10 secs before use. Initially 20mg once daily in the AM. May increase by 10–20mg per week if needed; max 60mg daily. Discontinue if no improvement seen after dose adjustment over 1 month. Switching from other methylphenidate products: discontinue and follow Quillivant XR titration schedule.

Administration

Give in the AM with or without food. Shake bottle for at least 10 secs to ensure proper dose is administered. Must be reconstituted with water prior to dispensing. Stable for up to 4 months after reconstitution.

Nursing Considerations

Give in the AM with or without food. Shake bottle for at least 10 secs to ensure proper dose is administered. Must be reconstituted with water prior to dispensing. Stable for up to 4 months after reconstitution.

Quillivant Xr Contraindications

Contraindications

During or within 14 days of MAOIs.

Quillivant Xr Boxed Warnings

Boxed Warning

Abuse, misuse, and addiction.

Quillivant Xr Warnings/Precautions

Warnings/Precautions

Do not substitute for other methylphenidate products on a mg-per-mg basis. High potential for abuse, misuse, and addiction; assess patient’s risk before prescribing. Assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other cardiac disease. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic or manic symptoms occur. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Risk for acute angle glaucoma. History of increased IOP or open angle glaucoma; monitor closely. Assess family history and evaluate for tics or Tourette’s syndrome before initiating; monitor for emergence or worsening, and discontinue if clinically appropriate. Monitor BP, HR, growth in children. Reduce dose or discontinue if paradoxical aggravation of symptoms occurs. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.

Quillivant Xr Pharmacokinetics

Absorption

Mean peak plasma concentration of 13.6 (±5.8) ng/mL occurred at a median time of 5 hours after dosing. Relative bioavailability of Quillivant XR compared to Methylphenidate IR oral solution (2x30 mg, q6h) is 95%.

Metabolism

Primarily via deesterification to alpha-phenyl-piperidine acetic acid (PPAA).

Elimination

Renal (90%). Half-life: 5.6 (±0.8) hours.

Quillivant Xr Interactions

Interactions

See Contraindications. Hypertensive crisis with MAOIs. May antagonize antihypertensive agents; monitor and adjust dose of antihypertensives as needed. Concomitant halogenated anesthetics may increase the risk of sudden BP and HR increase during surgery; avoid use. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.

Quillivant Xr Adverse Reactions

Adverse Reactions

Appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, hypertension; priapism, glaucoma, motor/verbal tics.

Quillivant Xr Clinical Trials

See Literature

Quillivant Xr Note

Not Applicable

Quillivant Xr Patient Counseling

See Literature

Images